GlaxoSmithKline to Buy Wyeth Vaccine Facility
- Share via
From Bloomberg News
GlaxoSmithKline, Europe’s largest drug maker, agreed to buy a U.S. vaccine production and research facility from Wyeth to increase production capacity of flu immunizations and to develop other treatments.
The terms of the acquisition are confidential, London-based Glaxo said. The Marietta, Pa., site will employ about 270 people.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
